Ovarian Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 112 expanded access programs, clinical trials, and compassionate use pathways listed for Ovarian Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with ovarian cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 44 programs are currently active or recruiting, with the remaining 68 in other lifecycle stages. Sponsors actively running programs in this area include AstraZeneca, M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), Alexander B Olawaiye, MD, and others.
By recruiting status
Snapshot of where every Ovarian Cancer program currently sits in its lifecycle.
- Active / Recruiting44
- Inactive68
Top sponsors
Organisations running the most Ovarian Cancer programs in the directory.
- AstraZeneca7 programs
- M.D. Anderson Cancer Center4 programs
- Merck Sharp & Dohme LLC4 programs
- National Cancer Institute (NCI)4 programs
- Alexander B Olawaiye, MD3 programs
- Incyte Corporation3 programs
- AbbVie2 programs
- Beth Israel Deaconess Medical Center2 programs
- Dana-Farber Cancer Institute2 programs
- Genmab2 programs
Ovarian Cancer programs (112)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 177Lu-BetaBart for Patients with Advanced or Hard-to-Treat Solid Tumors — Radiopharm Theranostics, Ltd
- Study on Using [18F]FAPI-74 PET Imaging for Detecting Cancer — National Cancer Institute (NCI)
- Study on Sac-TMT for Treating Advanced Ovarian Cancer Without HRD Mutation — Merck Sharp & Dohme LLC
- Study on the Safety and Effectiveness of COM701 in Treating Relapsed Platinum Sensitive Ovarian Cancer — Compugen Ltd
- Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
- Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
- Study on AZD8205 Alone or with Other Cancer Drugs for Advanced or Metastatic Solid Tumors — AstraZeneca
- Study on Biomarker-Driven Treatments for Persistent or Returning Rare Ovarian Tumors — Hoffmann-La Roche
- Study on Avutometinib Alone or with Defactinib for Recurrent Low-Grade Serous Ovarian Cancer with or without KRAS Mutation — Verastem, Inc.
- Study Comparing Azenosertib to Chemotherapy for Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancers with Cyclin E1 Protein — K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
- Study on INCB123667 for Treating Platinum-Resistant Ovarian Cancer with High Cyclin E1 Levels — Incyte Corporation
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
- Study on Side Effects and Disease Activity Changes with Mirvetuximab Soravtansine Combinations in Adults with Ovarian Cancer — AbbVie
- Study on Sacituzumab Tirumotecan Treatment Compared to Standard Care for Recurrent Ovarian Cancer — Merck Sharp & Dohme LLC
- Study on AMXI-5001 for Treating Advanced Cancers — AtlasMedx, Incorporated
- Trial of Vigil for Patients with Ovarian Cancer — Gradalis, Inc.
- Study on Autophagy Maintenance Therapy for Ovarian Cancer Patients — Medical University of South Carolina
- Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
- Study on Nivolumab with or without Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas — Brown University
- Continued Access Study for Patients Benefiting from Avelumab in Closing Pfizer-Sponsored Studies — Pfizer
- Study on Ubamatamab Combination Therapy for Adults with Platinum-Resistant Ovarian Cancer — Regeneron Pharmaceuticals
- Study on Lead-212 PSV359 Therapy for Patients with Solid Tumors — Perspective Therapeutics
- Study on New Treatments for Newly Diagnosed Stage III/IV Ovarian Cancer Before and After Surgery — University of Alabama at Birmingham
- Study on Oregovomab Plus Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer After Surgery — CanariaBio Inc.
- Study on PARP Inhibitor and CTLA-4 Blocker for BRCA-Related Ovarian Cancer — New Mexico Cancer Research Alliance
- Study on Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Treating Platinum-resistant Recurrent Ovarian Cancer — Merck Sharp & Dohme LLC
- Study on PF-07104091 as a Single Treatment and in Combination for Advanced Cancers — Pfizer
- Study on Gavo-cel (TC-210) for Treating Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Phase 3 Study on the Safety and Effectiveness of IMNN-001 with Chemotherapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer — Imunon
- Study on Relacorilant with Nab-paclitaxel and Bevacizumab for Advanced Ovarian, Peritoneal, or Fallopian-Tube Cancer — Corcept Therapeutics
- Continuation Study for Patients Who Benefited from a Previous Cancer Study with Olaparib — AstraZeneca
- Study on Sacituzumab Govitecan and Cisplatin for Treating Recurrent Ovarian and Endometrial Cancer Sensitive to Platinum — Icahn School of Medicine at Mount Sinai
- Study on the Safety, Tolerability, and Effects of Niraparib in Women with Ovarian Cancer — University of Miami
- Study on DPX-Survivac with Low Dose Cyclophosphamide and Pembrolizumab for Advanced and Recurrent Solid Tumors — ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Study on Dato-Dxd Alone and with Other Cancer Treatments for Advanced Solid Tumors (TROPION-PanTumor03) — AstraZeneca
- Study of Trastuzumab Deruxtecan with Bevacizumab vs. Bevacizumab Alone for First-line Maintenance in HER2-Expressing Ovarian Cancer — Daiichi Sankyo
- Study on Rina-S Plus Standard Treatment vs. Standard Treatment for Maintenance in Recurrent Platinum-sensitive Ovarian Cancer — Genmab
- Study Comparing Olaparib with Carboplatin and Paclitaxel to Carboplatin and Paclitaxel Alone in Advanced Ovarian Cancer — AstraZeneca
- Study Comparing INCB123667 with Chemotherapy for Platinum-Resistant Ovarian Cancer with Cyclin E1 Overexpression — Incyte Corporation
- Study Comparing INCB123667 with Chemotherapy for Platinum-Resistant Ovarian Cancer with Cyclin E1 Overexpression — Incyte Corporation
- Study on SPEDOX-6 for Advanced Cancers — University of California, Irvine
- Study on TT-10 and TT-4 as Single Agents and in Combination for Advanced Solid Tumors — Portage Biotech
- Study on BLU-222 for Advanced Solid Tumors — Blueprint Medicines Corporation
- Study on Beta-only IL-2 Immunotherapy for Advanced Solid Tumors — Medicenna Therapeutics, Inc.
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on [225Ac]-FPI-1434 Injection for Patients with Advanced Solid Tumors — Fusion Pharmaceuticals Inc.
- Study on TC-510 Cell Therapy for Advanced Cancers with Mesothelin Expression — TCR2 Therapeutics
- Study on the Safety and Effectiveness of NC410 and Pembrolizumab for Advanced Solid Tumors — NextCure, Inc.
- Study on ART0380 for Treating Advanced or Metastatic Solid Tumors — Artios Pharma Ltd
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Navicixizumab Alone or Combined with Other Treatments for Advanced Solid Tumors — OncXerna Theraputics, Inc.
- Study on Radspherin® for Patients with Advanced Epithelial Cancer with Peritoneal Metastasis Undergoing Chemotherapy and Surgery — Oncoinvent AS
- Study on SNS-101 Alone and with Cemiplimab for Advanced Solid Tumors — Sensei Biotherapeutics, Inc.
- Study on Vudalimab (XmAb20717) for Patients with Advanced Gynecologic and Genitourinary Cancers — Xencor, Inc.
- Study on ZN-c3 and Niraparib for Patients with Platinum-Resistant Ovarian Cancer — K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on APL-5125 for Adults with Advanced Solid Tumors — Apollo Therapeutics Ltd
- Study on the Safety and Effectiveness of REGN5668 with Cemiplimab or REGN4018 for Ovarian and Uterine Cancer — Regeneron Pharmaceuticals
- Study on Using Genetically Modified White Blood Cells to Treat Cancers with CD70 Marker — National Cancer Institute (NCI)
- Study on Using Genetically Modified T-Cells to Target Cancer Mutations in People with Metastatic Cancer — National Cancer Institute (NCI)
- Study on ADP-A2M4CD8 Alone and with Nivolumab for Treating MAGE-A4 Positive Ovarian Cancer in HLA-A2+ Patients (SURPASS-3) — Adaptimmune
- Study on Alpelisib and Olaparib for Treating Platinum-resistant High-grade Serous Ovarian Cancer Without BRCA Mutation — Novartis Pharmaceuticals
- Study on Neoadjuvant Chemotherapy with or without HCW9218 for Advanced Stage Ovarian Cancer — Haider Mahdi
- Study on Atezolizumab and Tivozanib for Treating Certain Hard-to-Treat Cancers — University of Florida
- Study on Belzutifan for Recurrent Clear Cell Ovarian Cancer — Dana-Farber Cancer Institute
- Study on Bevacizumab for Ovarian Cancer Found During Second-Look Surgery — M.D. Anderson Cancer Center
- Study on BI-1808 Alone and with Pembrolizumab for Treating Advanced Cancers — BioInvent International AB
- Study on Decitabine and Selinexor with Standard Chemotherapy to Overcome Drug Resistance in Ovarian Cancer — Loyola University
- EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer — M.D. Anderson Cancer Center
- Program to Access Botensilimab and Balstilimab Before Official Approval — Agenus Inc.
- Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. — AstraZeneca
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies — xCures
- Expanded Access Use of DKN-01 for Treating Advanced Solid Tumors — Leap Therapeutics, Inc.
- Study on the Safety and Effectiveness of TUB-040 for Ovarian and Non-Small Cell Lung Cancer — Tubulis GmbH
- Study on Gleolan for Detecting Ovarian Cancer During Surgery — NX Development Corp
- Study on Heated Chemotherapy for Primary Ovarian Cancer Patients — Andrea Jewell
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer — Canadian Cancer Trials Group
- Study on Intensive Chemoimmunotherapy and Intranodal Vaccines for Recurrent Ovarian Cancer — Roswell Park Cancer Institute
- Study on Intravenous T3011 Alone and with Other Treatments for Advanced Solid Tumors — ImmVira Pharma Co. Ltd
- Study on Mirvetuximab Soravtansine with Bevacizumab vs. Bevacizumab for Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) — AbbVie
- Study on NUV-868 Alone and with Olaparib or Enzalutamide for Adults with Advanced Solid Tumors — Nuvation Bio Inc.
- Study on ONC-392 and Pembrolizumab for Treating Platinum-Resistant Ovarian Cancer — OncoC4, Inc.
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer — Incyclix Bio
- Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer — Loyola University
- Phase I/IIa Study of AZD5335 Alone and with Other Cancer Treatments in Patients with Solid Tumors — AstraZeneca
- Phase II Study of IMNN-001 with Chemotherapy and BEV for Newly Diagnosed Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — Imunon
- Phase II Study of Pembrolizumab, Bevacizumab, and Cyclophosphamide for High-Grade Ovarian Cancer with Minimal Residual Disease After Initial Treatment — M.D. Anderson Cancer Center
- Study on Surgery With or Without Heated Chemotherapy for Advanced Ovarian Cancer — The Netherlands Cancer Institute
- Study on PRO1107 for Patients with Advanced Solid Tumors — Genmab
- Study on Luveltamab Tazevibulin vs. Chemotherapy for Women with Ovarian Cancer Expressing FOLR1 — Sutro Biopharma, Inc.
- Study on Regorafenib and Fulvestrant for Recurrent Low-Grade Serous Ovarian Cancer — Sarah K. Lynam MD
- Study on Abemaciclib and Letrozole with or without Metformin or Zotatifin for Endometrial or Low-Grade Serous Ovarian Cancer — Dana-Farber Cancer Institute
- Study on Re-sensitizing Carboplatin-resistant Ovarian Cancer with Kinase Inhibition of FAK — Michael McHale
- Study on the Safety and Effectiveness of ALX148 with Chemotherapy and Immunotherapy for Recurrent Platinum-resistant Ovarian Cancer — Alexander B Olawaiye, MD
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on BT5528 for Patients with Advanced Solid Tumors Linked to EphA2 Expression — BicycleTx Limited
- Study of AZD5305 Alone and with Other Cancer Treatments in Patients with Advanced Solid Tumors — AstraZeneca
- Study of BDC-3042 Alone and with Cemiplimab in Patients with Advanced Cancers — Bolt Biotherapeutics, Inc.
- Study on Carboplatin and Mirvetuximab Soravtansine for Initial Treatment in Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — University of Alabama at Birmingham
- Study on Chemotherapy with Pembrolizumab Followed by Maintenance with Olaparib for First-Line Treatment of Women with Advanced Ovarian Cancer Without BRCA Mutation — Merck Sharp & Dohme LLC
- Study on Intravenous and Abdominal Paclitaxel and Oral Nilotinib for Abdominal Cancer Spread from Various Primary Cancers — National Cancer Institute (NCI)
- Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors — NGM Biopharmaceuticals, Inc
- Study on TROP2 CAR-Engineered IL15-Transduced Cord Blood NK Cells for Treating Resistant Ovarian, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer — M.D. Anderson Cancer Center
- Study on PC14586 for Patients with Advanced Solid Tumors with a TP53 Y220C Mutation (PYNNACLE) — PMV Pharmaceuticals, Inc
- Study on Tuvusertib Combined with Niraparib or Lartesertib for Epithelial Ovarian Cancer — EMD Serono Research & Development Institute, Inc.
- Study on Maintenance Olaparib for Advanced Ovarian Cancer Patients Without BRCA Mutation but With Homologous Recombination Deficiency — Alexander B Olawaiye, MD
- Study on Vaccination for Ovarian Cancer Patients Using Dendritic Cell/Tumor Fusions with GM-CSF and Imiquimod — Beth Israel Deaconess Medical Center
- Study on Zafirlukast for Treating Ovarian Cancer That Has Returned Based on Tumor Markers — Beth Israel Deaconess Medical Center
- Study on ZEN003694 and Talazoparib for Patients with Recurrent Ovarian Cancer — Alexander B Olawaiye, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Ovarian Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.